BCL2 and acute myeloid leukemia: The development of small molecule inhibitors of BCL2 family anti-apoptotic proteins resulted in a paradigm shift for the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) (Roberts, 2020).